NSCLC harboring EGFR exon‐20 insertions after the regulatory C‐helix of kinase domain responds poorly to known EGFR inhibitors

• Published in: International journal of cancer Vol. 139; no. 1; pp. 171 - 176
• Main Authors: Yang, Mengmeng, Xu, Xiaoxi, Cai, Jie, Ning, Jinying, Wery, Jean Pierre, Li, Qi‐Xiang
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2016
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - pathology; Cell Line, Tumor; Drug Resistance, Neoplasm - genetics; EGFR‐exon‐20 insertion; Epidermal growth factor; Erbitux; Exons - genetics; Humans; Kinases; Lung cancer; Medical research; Mutation; PDX; Protein Kinase Inhibitors; Quinazolines - administration & dosage; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - genetics; TKI; Xenograft Model Antitumor Assays; TKI; PDX; EGFR-exon-20 insertion; Erbitux
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.30047

Anecdote clinical observations hint that non‐small cell lung cancer (NSCLC) with exon‐20 insertions might respond poorly to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), contrasting to those with classic mutations. Lack of patient‐derived experimental models has been a major hurdle for the discovery of new treatment for the diseases. We established two NSCLC‐PDXs harboring two different exon‐20 insertions, LU0387‐adenocarcinoma (ADC) with a nine‐base insertion at 2319 (H773‐V774insNPH) and LU3075‐squamous cell carcinoma (SCC) with a nine‐base insertion at 2316 (P772‐H773insDNP). Both insertions immediately follow the regulatory C‐helix of the kinase domain. Contrary to the generally good responses to EGFR inhibitors observed in PDXs with classic mutations, both exon‐20 insertions are largely resistant to cetuximab and TKIs in vivo, suggesting fundamental difference from the classic EGFR mutations, consistent with the poor response rate to TKI seen in anecdotal clinic reports. It is worth noting that although responses are generally poor, they differ between the two exon‐20 mutants depending on the type of TKI. In vitro drug sensitivity assays using established primary cell lines from our two PDXs largely confirmed the in vivo data. Our data from patient‐derived experimental models confirmed that exon‐20 insertions in domain immediately following the C‐helix confer poor response to all known EGFR inhibitors, and suggested that these models can be utilized to facilitate the discovery of new therapies targeting NSCLC harboring exon‐20 insertions. What's new? Anecdotal clinical observations suggest that, in contrast to classic mutations, non‐small cell lung cancers (NSCLCs) with exon‐20 insertions respond poorly to EGFR tyrosine kinase inhibitors. The lack of patient‐derived experimental models, however, has been a major hurdle for the discovery of new treatments. Here, the authors report establishing for the first time two NSCLC‐patient derived xenografts with two different exon‐20 insertions, both of them following the C‐helix domain. The data confirm that such exon‐20 insertions confer poor response to all known EGFR inhibitors. The models may be used to facilitate the discovery of new therapies targeting NSCLCs harboring exon‐20 insertions.